According to a new market report published by Transparency Market Research "Dilated Cardiomyopathy Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020," the global dilated cardiomyopathy market was valued at USD 651.0 million in 2013 and is estimated to reach USD 328.6 million in 2020 declining at a CAGR of (7.0%) from 2014 to 2020.

Dilated cardiomyopathy (DCM) is one of the myocardium disorders associated with cardiac dysfunction. Hypertrophic, dilated, arrhythmogenic right ventricular and restrictive cardiomyopathies represent the four major types of cardiomyopathies, and the others fall under unclassified category. DCM accounts for one of the major causes of heart failure and is characterized by the presence of dilated heart muscles which lead to enlargement of the heart. This in turn, hampers blood pumping capacity of the heart and with time, DCM spreads to the right ventricle, atria and ultimately results in heart failure. The occurrence of dilated cardiomyopathy in males is more prevalent than in females at a ratio of 3:1. Patients with mild DCM can lead normal lives by regular intake of medication along with some lifestyle changes, while patients with severe DCM need a heart transplant.

Browse the full Dilated Cardiomyopathy Therapeutics Market Report @ :
http://www.transparencymarketresearch.com/dilated-cardiomyopathy-market.html

Oral medications and implantable medical devices constitute the key treatment options for DCM. Oral medications decrease the size of the heart by acting against high blood pressure and coronary artery disease. Devices implanted in DCM patients refer to implantable cardioverter–defibrillator (ICD), pacemakers (biventricular pacing) and heart pumps. The dilated cardiomyopathy therapeutics market is anticipated to decline throughout the forecast period from 2014 to 2020. This is majorly attributed to patent expirations, potential side effects of the drugs and increasing efficiency of alternative therapies.

The market for dilated cardiomyopathy therapeutics is segmented majorly by drug class and geography. The various drug classes considered include aldosterone antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers and beta blockers. ACE inhibitors are considered as the first line of treatment in patients suffering from dilated cardiomyopathy, and these drugs help improve pumping capacity of the heart by decreasing the activity of rennin-angiotensin-aldosterone system (RAAS). The sales of ACE inhibitors are anticipated to reduce during the forecast period from 2014 to 2020 majorly due to patent expiration of the prominent drugs and increasing competition from generic drugs, which will further hamper market growth.

Browse the full Dilated Cardiomyopathy Therapeutics Market press release @ :
http://www.transparencymarketresearch.com/pressrelease/dilated-cardiomyopathy-market.htm

Aldosterone antagonists reduce cardiac activity and blood pressure. Eplerenone and spironolactone are the two major aldosterone antagonists used in the treatment of dilated cardiomyopathy. This drug class will record highest growth rate owing to their increased acceptance and increased survival rate of patients with DCM. Angiotensin II receptor blockers (ARBs) in combination with ACE inhibitors are usually preferred to treat dilated cardiomyopathy as these drugs block the RAAS pathway, thereby reducing the pressure exerted by the heart. Clinical trials have proven the successful effect of ARBs such as valsartan, losartan and candersartan against DCM. However, loss of patent exclusivity of major drugs followed by the increased efficiency of combination therapies in treatment of DCM might hamper market growth and result in declined sales in the forthcoming years.

Currently, there is no drug approved specifically for the treatment of dilated cardiomyopathy; however, the above mentioned drugs have been studied for their effectiveness in treatment of DCM that has lead to doctors prescribing these medications. This factor provides lucrative opportunity for the market payers to develop and commercialize specific drugs against dilated cardiomyopathy. Increasing efficiency of alternative therapies such as implantable medical devices and gene therapy might further play a role in decelerating market growth.

Get Free Sample Report Dilated Cardiomyopathy Therapeutics Market :
http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=2293

Major players competing in this market are Novartis International AG, Merck Co. & Inc., and AstraZeneca plc that together accounted for more than 70% of the total dilated cardiomyopathy therapeutics market revenue. Other players include Pfizer, Inc., Sanofi Aventis, GlaxoSmithKline plc and Valeant Pharmaceuticals, Inc. Increasing investments by market players towards the development of dilated cardiomyopathy drugs will favor market growth post their approval. For instance, Array BioPharma, Inc. (ARRY – 797), Celladon Corporation (MYDICAR) and Vericel Corporation (IXCELL-DCM, Catheter-DCM, IMPACT-DCM) constitute some of the companies whose drugs are in pipeline (phase I or Phase II).

The global dilated cardiomyopathy therapeutics market is segmented into the following categories:

Dilated cardiomyopathy therapeutics market, by drug class

Aldosterone antagonists

Angiotensin-converting enzyme (ACE) inhibitors

Angiotensin II receptor blockers (ARBs)

Beta-blockers

Dilated cardiomyopathy therapeutics market, by pipeline drugs

ARRY-797

ixCELL-DCM

MYDICAR

OR-1

CAP-1002

Dilated cardiomyopathy therapeutics market, by geography

North America

Europe

Asia Pacific

Rest of the World (RoW)
 
About Us :

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.